my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
MorphoSys AG announced that it has received a clinical milestone payment from Centocor Ortho Biotech Inc. in connection with the regulatory filing of a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases. more
MorphoSys AG announced that it will receive a milestone payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of ophthalmology. The news marks the entry of the third HuCAL-derived antibody into human clini more
MorphoSys AG announced that it will receive a clinical milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases. Th more
Abiraterone acetate Nature Reviews Drug Discovery 10, 573 (2011). doi:10.1038/nrd3516 Authors: Christopher J. Logothetis, Eleni Efstathiou, Fil Manuguid & Peter Kirkpatrick In April 2011, abiraterone acetate (Zytiga; Centocor Ortho Biotech), in combination with prednisone, wa more
What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market. Our report gives you revenue forecasts to 2021 for treat more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
Overview Business Strategy Management Team Board Of Directors Scientific Advisory Board Clinical Advisory Board From Heparin to Glycodrugs Endotis Pharma Drug Discovery Engine Targeted Diseases R&D Programs Management Team Management Board Charles Woler, MD Chairman and Chief Executive Officer Charl more
Home Font Size: 1 2 3 Send to a Friend Company Mission History About Us Awards Contact Driving Directions Technology Product Pipeline MORAb-004 Farletuzumab MORAb-009 Preclinical Pipeline Clinical Trials Farletuzumab MORAb-004 MORAb-009 Partnerships Research Alliances News & Even more
Schriftgröße Startseite | Kontakt | Übersicht | Janssen-Cilag Websites Datenschutzerklärung Nutzungs- und Haftungsbedingungen > Fachkreise-Login Registrierung DocCheck®-Login Unternehmen Therapiegebiete Produkte Patientenbelange Partnerschaft Versorgung Karriere Delphi-Studienreihe Zukunftsprei more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
